| 產(chǎn)品名稱 | CYT 387 - Momelotinib |
| 產(chǎn)品貨號 | Axon 1681 CAS [1056634-68-4] MF C23H22N6O2MW 414.46 Purity: 99% Soluble in DMSO Description Selective and ATP-competitive Janus Kinase JAK1/JAK2 inhibitor, with IC50 to be 11 and 18 nM for JAK1 and JAK2 respectively and far less activity against other kinases, including JAK3 (IC50=155 nM) References Certificates Categories Extra info A Pardanan et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009, 23, 1441–1445. ? JW Tyner et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010, 115(25), 5232-5240. ? S Verstovsek.?Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program. 2009, 636-642. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Epigenetics JAK-STAT EC 2.7.10.2 JAK JAK1 and JAK2 inhibitor Chemical name N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Parent CAS No. [1056634-68-4] Order Size Unit Price Stock 5 mg €90.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
CYT 387 - MomelotinibAxon 1681 CAS [1056634-68-4] MF C23H22N6O2
Description
Selective and ATP-competitive Janus Kinase JAK1/JAK2 inhibitor, with IC50 to be 11 and 18 nM for JAK1 and JAK2 respectively and far less activity against other kinases, including JAK3 (IC50=155 nM)
JAK1 and JAK2 inhibitor
Chemical nameN-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Parent CAS No.[1056634-68-4] |
| 產(chǎn)品資料 |
